Molecular Pharming Market to Grow with a CAGR of 7.74% through 2029
Increased research in bio-farming techniques and growing demand for
cost-effective, scalable methods of producing vaccines is expected to drive the
Global Molecular Pharming Market growth in the forecast period, 2025-2029.
According to TechSci Research report, “Molecular
Pharming Market – Global Industry Size, Share, Trends, Competition, Forecast & Opportunities, 2029F”, the Global Molecular Pharming Market
stood at USD 1.58 Billion in 2023 and is anticipated to grow with a CAGR of 7.74%
in the forecast period through 2029. The global molecular pharming market is
witnessing substantial growth due to several driving factors. Increasing investments in R&D activities,
coupled with government support for molecular pharming, are propelling this
growth. The rising global burden of diseases and
the need for affordable therapeutic solutions are contributing to the market
expansion. The environmental sustainability of plant-based production presents
an attractive, low-cost alternative to traditional pharmaceutical manufacturing
methods, making molecular pharming a promising avenue for future pharmaceutical
development.
The global molecular pharming market is a rapidly
evolving sector that holds promising potential for the future of
pharmaceuticals and healthcare. Molecular pharming, also known as pharmaceutical
farming, is a cutting-edge biotechnological process that involves using
genetically modified plants or animals to produce pharmaceutical proteins.
These proteins serve as active components in vaccines, antibodies, and
therapeutic drugs, thereby opening up new avenues in healthcare. The global
molecular pharming market is anticipated to witness substantial growth in the
coming years, driven by increasing investment in research and development and
the unmet need for efficient, cost-effective medicinal products. The
burgeoning demand for therapeutics for chronic diseases, such as cancer and
autoimmune disorders, is likely to boost the market growth. One of the key
advantages of molecular pharming lies in its potential for scale-up production,
promising a sustainable solution for large-scale production of pharmaceutical
proteins. Unlike traditional manufacturing methods, molecular pharming is
considerably less expensive and environmentally friendly. This is particularly
important in the context of the escalating global demand for
biopharmaceuticals.
The global molecular pharming market is experiencing
significant growth, fueled by remarkable advancements in genetic engineering
and genomics. Breakthroughs in CRISPR gene-editing technology and next-generation
sequencing have not only expanded the possibilities of molecular pharming but
have also opened up new avenues for drug discovery and personalized medicine.
By providing precise and efficient tools for manipulating genes and studying
molecular interactions, these technological innovations have paved the way for
the development of novel therapeutics and tailored treatments that hold immense
potential for improving healthcare outcomes on a global scale. The
field of molecular pharming is not only revolutionizing the pharmaceutical
landscape but also addressing critical challenges in the production of
biopharmaceuticals. Traditional methods of manufacturing biologics often
involve complex and costly processes, which can limit their accessibility and
affordability. However, molecular pharming offers a more sustainable and
scalable approach by harnessing the power of plants and other expression
systems to produce high-value proteins and antibodies. This innovative
production platform not only reduces production costs but also offers greater
flexibility in terms of scalability and customization.
The applications of molecular pharming
extend beyond the production of therapeutics alone. With ongoing research and
development, this field has the potential to support advancements in other
areas such as agriculture, biofuels, and industrial enzymes. By leveraging the
power of molecular biology and plant biotechnology, scientists are exploring
the possibilities of using genetically modified plants to produce valuable
compounds for various industries. This interdisciplinary approach has the
potential to drive innovation, sustainability, and economic growth in multiple
sectors. The rapid progress in genetic engineering, genomics, and related
technologies has propelled the molecular pharming industry into a promising era
of drug discovery, personalized medicine, and sustainable biomanufacturing.
With its potential to revolutionize the pharmaceutical landscape and address
critical challenges in biopharmaceutical production, molecular pharming is
poised to shape the future of healthcare and contribute to a more sustainable
and inclusive global economy.Despite the promising prospects, the market faces
certain challenges. Regulatory hurdles, ethical issues related to GMO use, and
the technical complexities associated with the extraction and purification of
pharmaceutical proteins are barriers that need to be surmounted.The global
molecular pharming market is poised for significant growth, driven by
technological advancements, increasing disease prevalence, and the need for
efficient, sustainable pharmaceutical production methods. However, overcoming
the inherent challenges in this field is critical to fully harness its
potential. Nevertheless, with continuous research and development efforts,
molecular pharming is likely to play a key role in the future of
pharmaceuticals and healthcare.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Molecular Pharming Market”
The Global Molecular Pharming Market is segmented into
crop source, technology, application, end user, regional distribution, and
company.
Based on application, Proteins & Protein-Based Materials segment is expected to exert its dominance in the global molecular pharming
market. This can be attributed to the crucial role that proteins play in
various biological processes, as well as the continuous advancements in protein
engineering technologies. The versatility of protein-based materials
in the development of innovative bioproducts has opened up new avenues for
their extensive application in the field of molecular pharming. The
utilization of proteins and protein-based materials in molecular pharming
offers numerous advantages. These include enhanced production efficiency,
improved scalability, and the ability to produce complex and high-value
biotherapeutics. The use of protein engineering techniques allows for the
optimization of protein expression and functionality, leading to the development
of more effective and targeted therapies. The development of
novel protein-based materials enables the creation of advanced drug delivery
systems and tissue engineering scaffolds, further expanding the potential
applications of molecular pharming. With these advancements and opportunities,
the 'Proteins & Protein-Based Materials' segment is well-positioned to
drive the growth and shape the future of the molecular pharming industry. As
research and development efforts continue to push the boundaries of protein
science, we can expect even more breakthroughs in biopharmaceutical production
and therapeutic applications. The integration of molecular pharming into the
pharmaceutical landscape has the potential to revolutionize drug discovery and delivery,
ultimately improving patient outcomes and transforming the healthcare industry
as a whole.
Based on region, North America segment is expected to
grow during the forecast period. The North American molecular pharming
market is expected to capture a significant market share in terms of revenue.
This is primarily due to the region's proactive adoption of new technologies
and innovative approaches. With a projected high compound annual growth rate
(CAGR), North America stands as a pioneer in embracing advancements in
molecular pharming. The success of the market can be attributed to various
factors. Expanding government initiatives play a crucial role in
promoting the implementation of modern agricultural technologies. These
initiatives not only encourage research and development but also provide
financial support and incentives to companies in the molecular pharming sector.
This, in turn, fosters innovation and drives the growth of the market. The presence of well-established infrastructure
in North America contributes to the market's success. The region boasts
state-of-the-art facilities, advanced laboratories, and a robust supply chain
network. This infrastructure not only facilitates the production and
distribution of molecular pharming products but also ensures their quality and
safety. As a result, North American companies can deliver reliable and
high-quality products to meet the growing demand. While North America leads the
way, the Asia Pacific region has also emerged as a key player in the molecular
pharming market. Countries like India, Sri Lanka, and Nigeria have witnessed
significant advancements in the adoption of contemporary precision agricultural
technologies. Government projects aimed at fostering the adoption of these
technologies have played a pivotal role in driving increased production and
further propelling the growth of the market in these emerging nations. North
American molecular pharming market's success can be attributed to a combination
of factors such as expanding government initiatives, well-established
infrastructure, and the region's pioneering spirit in embracing new
technologies. With the Asia Pacific region also making strides in this field,
the future of the molecular pharming market looks promising, opening up new
opportunities for innovation, growth, and increased production.
Major companies operating in
Global Molecular Pharming Market are:
- Agrenvec S.L
- Diamante SRL
- Leaf Systems International Limited
- Medicago Inc
- Meristem Therapeutics S.A.
- Moolec Science SA
- ORF Genetics
- Pfizer, Inc.
- ProdiGene Inc.
- Protalix Biotherapeutics, Inc.
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The future of the global molecular pharming market is
expected to be vibrant and dynamic. With advancements in biotechnology and
genetic engineering, the production of pharmaceuticals using genetically
modified plants and animals is likely to escalate. This burgeoning field
promises to deliver new, cost-effective solutions for the production of
vaccines, antibodies, and other therapeutic proteins. As the world continues to
face new health challenges, the demand for more accessible and affordable
treatments is expected to drive significant growth in the molecular pharming
market.,” said Mr. Karan Chechi, Research Director of TechSci Research, a
research-based management consulting firm.
“Molecular Pharming Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Crop Source (Maize, Barley, Tobacco, Safflower, Rice, Alfalfa), By Technology (Gene Gun, Agroinfiltration, Electroporation, Agrobacterium-Mediated Gene Transfer, Others), By Application (Recombinant Antibodies, Hormones, Vaccines, Industrial Enzymes, Proteins & Protein-Based Materials, Technical Reagents, Nutritional Products, Others), By End User (Biotechnology & Pharmaceutical Companies, Contract Manufacturing Organizations, Others), By Region and Competition, 2019-2029F”, has evaluated
the future growth potential of Global Molecular Pharming Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also identifies
and analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Molecular Pharming Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com